Format

Send to

Choose Destination
Biol Blood Marrow Transplant. 2017 Apr;23(4):691-696. doi: 10.1016/j.bbmt.2016.12.639. Epub 2017 Jan 3.

Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients.

Author information

1
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Electronic address: osala@fredhutch.org.
2
Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; SWOG Statistical Center, Seattle, Washington.
3
Adaptive Biotechnologies, Seattle, Washington.
4
Department of Laboratory Medicine, University of Washington, Seattle, Washington.
5
Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
6
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
7
Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, California.

Abstract

We used next-generation sequencing (NGS) of the immunoglobulin genes to evaluate residual disease in 153 specimens from 32 patients with adult B cell acute lymphoblastic leukemia enrolled in a single multicenter study. The sequencing results were compared with multiparameter flow cytometry (MFC) data in 66 specimens (25 patients) analyzed by both methods. There was a strong concordance (82%) between the methods in the qualitative determination of the presence of disease. However, in 17% of cases, leukemia was detected by sequencing but not by MFC. In 54 bone marrow (BM) and peripheral blood (PB) paired specimens, the burden of leukemia detected by NGS was lower in PB than in BM, although it was still detectable in 68% of the 28 paired specimens with positive BM. Lastly, patients without disease detected by NGS or MFC had a 5-year relapse free survival of > 80%. The results suggest that residual disease detection by immunoglobulin gene sequencing is an extremely sensitive technique and may identify patients that might benefit from transplantation. Moreover, the increased sensitivity of the method may allow frequent peripheral blood testing to supplement marrow sampling to measure disease response.

KEYWORDS:

Acute lymphoblastic leukemia; Minimal residual disease

PMID:
28062215
PMCID:
PMC5465962
DOI:
10.1016/j.bbmt.2016.12.639
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center